Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IOBT | US
-0.05
-4.03%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.19
1.26
1.27
1.14
IO Biotech Inc. a clinical-stage biopharmaceutical company develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate IO102-IO103 which is designed to target immunosuppressive proteins such as Indoleamine 23-dehydrogenase (IDO) and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma as well as in phase 1 clinical trial to treat lung head and neck bladder and melanoma cancer. It also develops IO112 a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen Denmark.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
82.8%1 month
74.7%3 months
153.1%6 months
118.4%-
-
0.85
0.02
0.02
1.36
-
-
-93.16M
78.40M
78.40M
-
-
-
-
-87.66
0.31
1.31
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.25
Range1M
0.29
Range3M
1.00
Rel. volume
0.96
Price X volume
154.43K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals Inc | CASI | Biotechnology | 5.5 | 85.04M | -1.43% | n/a | 167.26% |
| Ovid Therapeutics Inc | OVID | Biotechnology | 1.19 | 84.46M | -2.46% | n/a | 18.40% |
| X4 Pharmaceuticals Inc | XFOR | Biotechnology | 0.496 | 83.58M | -4.52% | 4.00 | 82.82% |
| CannaRoyalty Corp | CNNRF | Biotechnology | 4.03 | 82.64M | -0.58% | n/a | 141.66% |
| PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.59 | 81.92M | 0.63% | n/a | 6.06% |
| Ikena Oncology Inc. Common Stock | IKNA | Biotechnology | 1.69 | 81.56M | -1.17% | n/a | 6.36% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 3 | 81.17M | -2.28% | n/a | 1.90% |
| Audentes Therapeutics Inc | BOLD | Biotechnology | 3.03 | 79.37M | -0.66% | n/a | 0.47% |
| ALXO | ALXO | Biotechnology | 1.5 | 79.01M | 1.35% | n/a | 10.97% |
| Cidara Therapeutics Inc | CDTX | Biotechnology | 11.22 | 78.97M | -0.36% | n/a | 3.28% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Urban One Inc | UONEK | Broadcasting - Radio | 1.01 | 53.54M | -3.35% | n/a | 268.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.36 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.85 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 153.12 | - | Riskier |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 78.40M | - | Emerging |